Equities
  • Price (EUR)120.85
  • Today's Change1.95 / 1.64%
  • Shares traded0.00
  • 1 Year change-6.29%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.

  • Revenue in USD (TTM)9.25bn
  • Net income in USD850.00m
  • Incorporated1996
  • Employees40.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
announced
Transaction
value
Lenco Diagnostic Laboratories IncDeal completed01 Feb 202401 Feb 2024Deal completed3.78%111.00m
Steward Health Care System LLC-Outreach Laboratory Services Business Select AssetsDeal completed08 Jan 202408 Jan 2024Deal completed-6.13%--
Haystack Oncology IncDeal completed27 Apr 202327 Apr 2023Deal completed-9.23%450.00m
Data delayed at least 15 minutes, as of Mar 28 2024 19:27 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.